** Shares of Amgen AMGN.O rise nearly 1% to $286.50 in aftermarket trading
** Drugmaker reports Q1 adj. profit per share of $4.90, beating estimates of $4.30
** Company's quarterly revenue up 9% to $8.1 billion
** Says U.S. FDA has lifted its clinical hold on an early-stage trial of an experimental weight-loss drug known as AMG 513
** Reiterates annual adj. profit per share to be between $20 and $21.20; 2025 revenue to be in the range of $34.3 billion to $35.7 billion
** Adds 2025 projection includes the estimated impact of implemented tariffs, but does not account for any tariff that could be implemented in the future, including potential sector-specific ones
** Stock rose 9% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.